
EcoGenome: Developing predictive tests for personalized cancer treatment strategies.
EcoGenome, founded with a mission to revolutionize cancer treatment, focuses on developing prognostic and predictive tests that enhance personalized treatment strategies for cancer patients. By identifying individual tumor genetic vulnerabilities, EcoGenome aims to provide more precise and informed cancer therapy choices. Their primary product offerings include diagnostic tests specifically designed for prostate cancer, which help tailor treatment plans based on the genetic profile of a patient's tumor.
Notable figures affiliated with EcoGenome include leading oncologists and geneticists who contribute to the company's innovative approach. The company has garnered attention from key investors in the biotechnology sector, enabling significant advancements in their research and development efforts. EcoGenome's impact is marked by its contribution to the field of personalized medicine, offering hope for more effective and targeted cancer therapies that improve patient outcomes.

Personal Genome Diagnostics
personalgenome.com

Inform Genomics
informgenomics.com

PrognosDx Health

Foundation Medicine

GenomOncology
genomoncology.com

ProstaGene

Vyant Bio

D2G Oncology
d2g-oncology.com

Geneicd

Geneos Therapeutics
geneostx.com

Genetron Health
genetronhealth.com

Geneius
geneius.com

OncoPrecision
oncoprecision.bio

MyCancerDB
ennov1.com

Empiri
empiricancer.com
Companies similar to EcoGenome include Personal Genome Diagnostics, Inform Genomics, PrognosDx Health and Foundation Medicine.
EcoGenome was founded in 2021.
EcoGenome's headquarters is located in Wynnewood, PA, US.
EcoGenome's most recent funding round was for $2M (USD) in November 2022.
As of Nov 3, 2022, EcoGenome has raised a total of $2M (USD).
EcoGenome has 175 employees as of Feb 5, 2024.